ALT5 Sigma Corporation (NASDAQ: ALTS)(FRA: 5AR1) (the “Company” or “ALT5”), a fintech and digital asset treasury (DAT) company specializing in turnkey, crypto-related solutions for institutions and merchants, today announced the appointment of industry veteran Jonathan Hugh as CFO of the company.

Following ALT5 Sigma’s recently announced $1.5 billion financing and the launch of the company’s $WLFI Treasury Strategy, we are pleased to announce the appointment of Jonathan Hugh as Chief Financial Officer. His appointment further strengthens the company’s leadership team at a pivotal stage in its growth.

“Jonathan is a highly accomplished senior executive with deep international experience across digital assets, commodity trading, and technology,” said Peter Tassiopoulos, CEO of ALT5 Sigma. “His proven ability to scale high-growth businesses, combined with his expertise in financial strategy and global markets, will be invaluable as we accelerate the global expansion of our Crypto-as-a-Service platform and advance our $WLFI treasury initiatives.”

Jonathan brings over 25 years of senior finance and commercial leadership experience in Digital Assets, Technology, Energy, and Commodities Trading, working with both public and private companies ranging from large-cap multinationals to agile high-growth ventures. He previously served as CFO of leading digital asset firms GSR International Ltd, a global market maker, and Zodia Custody Ltd, a regulated institutional custodian. Throughout his career, he has led numerous M&A transactions, executed multiple growth strategies and built robust financial control, compliance and reporting systems to support rapid innovation.

Jonathan is a member of the Institute of Chartered Accountants of England and Wales and holds an MA in Law from Cambridge University. His appointment underscores ALT5 Sigma’s commitment to attracting world-class leadership talent to drive execution of its strategic vision and deliver long-term value for shareholders.

About ALT5 Sigma

ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) or (the “Company”) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. Since June of 2025, the Company has been a member of the Russell Microcap Growth^®, Russell 3000E^®, and Russell 3000E Growth^® Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russell Microcap^® Index since June of 2024. The Company recently initiated a $WLFI Treasury Strategy, leveraging a portfolio of digital assets as a strategic component of its balance sheet. This initiative is designed to generate long-term value through disciplined acquisition and deployment of digital assets, while showcasing the Company’s capabilities in digital asset payment solutions. The strategy not only strengthens the Company’s financial position but also demonstrates the practical, institutional-grade application of its next-generation technology stack in real-world treasury operations.

Founded in 2018, the Company provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. The Company, through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Sigma has processed over $6 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

The Company is working on the separation of its biotech business that will move forward under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. The Company’s patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted JAN123 Orphan Drug Designation for treatment of CRPS.

About World Liberty Financial

World Liberty Financial (WLFI) is a pioneering decentralized finance (DeFi) protocol and governance platform dedicated to empowering individuals through transparent, accessible, and secure financial solutions. Inspired by the vision of President Donald J. Trump, WLFI seeks to democratize access to DeFi by creating user-friendly tools that bring the benefits of decentralized finance to a broader audience. WLFI plans to be at the forefront of DeFi, offering an intuitive, robust platform that empowers users to participate actively in the financial future.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the expected use of proceeds from the Offerings, the Company’s expectation to initiate its $WLFI Treasury Strategy, the profitability and prospective growth of ALT5’s platforms and business that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion, and statements regarding the Company’s potential separation plans of its biotech business. This press release also contains general statements relating to risks that the Company’s potential separation plans of its biotech business and the potential for JAN123 to treat CRPS, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company’s interests in Alyea without specificity of the scope or methods thereof.

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250814426464/en/